Atlas Trials

Forma Therapeutics, Inc.

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Forma Therapeutics, Inc.

RecordFirmDate
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke (NCT05953584)Forma Therapeutics, Inc.2023-06-20
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease (NCT06198712)Forma Therapeutics, Inc.2023-01-12
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) (NCT05568225)Forma Therapeutics, Inc.2022-11-15
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease (NCT04987489)Forma Therapeutics, Inc.2022-03-28
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) (NCT04624659)Forma Therapeutics, Inc.2021-01-29
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis (NCT04004325)Forma Therapeutics, Inc.2019-05-17
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients (NCT03815695)Forma Therapeutics, Inc.2018-12-11
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation (NCT03684811)Forma Therapeutics, Inc.2018-11-01

Track Forma Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.